

**CLAIM AMENDMENTS**

This listing of claims will replace all prior versions and listings of claims in the application:

1. (currently amended) A method of treating a mammal with psoriasis, comprising systemically administering to said mammal an amount of an EGFR/HER1 ~~antagonist~~ antibody effective to treat psoriasis.
2. (canceled)
3. (currently amended) A method according to claim 2 1 wherein the antibody is a monoclonal antibody specific for EGFR/HER1 or a fragment that comprises the hypervariable region thereof.
4. (original) A method according to claim 3 wherein the monoclonal antibody is chimerized or humanized.
5. (original) A method according to claim 3 wherein the monoclonal antibody inhibits EGFR/HER1 phosphorylation.
- 6-44. (canceled)
45. (new) A method according to claim 1 wherein the mammal is a human.
46. (new) A method according to claim 1 wherein the antibody is administered intravenously.
47. (new) A method according to claim 1 wherein the antibody comprises the following CDRs having the following amino acid sequences:

CDR1, SEQ ID 2;

CDR2, SEQ ID 4;

CDR3, SEQ ID 6;

CDR4, SEQ ID 8;

CDR5, SEQ ID 10;

CDR6, SEQ ID 12.

48. (new) A method according to claim 47 wherein the antibody is 225 or C225.